Convalescent Plasma Studies Launched by the U.S. NIH

Additional clinical trials funded by the US National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma treatments for patients hospitalized with COVID-19. These studies are needed as observational studies indicate that convalescent plasma may improve outcomes among severely ill and hospitalized patients with COVID-19. 

However, prospective, well-controlled randomized trials are needed to generate sufficient data on whether convalescent plasma is effective and safe for the treatment of COVID-19, stated the NIH’s press release published on September 22, 2020.